Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramon Colomer

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Oncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine and paclitaxel in metastatic breast cancer: a reviewRamon Colomer
Women'S Health (London, England)|October 7, 2009
Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancerRamon Colomer
Medicina Clinica|March 10, 2009
[Fatty acid synthase: a new anti-tumor target]Teresa Puig, Rut Porta, Ramon Colomer
Oncology Reports|July 16, 2004
Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cellsJavier A Menendez, Ramon Colomer, Ruth Lupu
Drug News & Perspectives|October 26, 2005
Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancerJavier A Menendez, Ruth Lupu, Ramon Colomer
Breast Cancer Research and Treatment|March 5, 2004
Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)Javier A Menendez, Ruth Lupu, Ramon Colomer
Medical Hypotheses|December 21, 2004
Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesisJavier A Menendez, Ramon Colomer, Ruth Lupu
Medical Hypotheses|December 21, 2004
Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?Javier A Menendez, Ramon Colomer, Ruth Lupu
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 16, 2010
Targeting cytoskeleton reorganisation as antimetastatic treatmentMiguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer
Advances in Experimental Medicine and Biology|May 24, 2008
Her-2/neu-induced "cytokine signature" in breast cancerAlejandro Vazquez-Martin, Ramon Colomer, Javier A Menendez
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Oncology (Williston Park, N.Y.)|February 3, 2005
Gemcitabine and paclitaxel in metastatic breast cancer: a reviewRamon Colomer
Women'S Health (London, England)|October 7, 2009
Gemcitabine in combination with paclitaxel for the treatment of metastatic breast cancerRamon Colomer
Medicina Clinica|March 10, 2009
[Fatty acid synthase: a new anti-tumor target]Teresa Puig, Rut Porta, Ramon Colomer
Oncology Reports|July 16, 2004
Inhibition of tumor-associated fatty acid synthase activity enhances vinorelbine (Navelbine)-induced cytotoxicity and apoptotic cell death in human breast cancer cellsJavier A Menendez, Ramon Colomer, Ruth Lupu
Drug News & Perspectives|October 26, 2005
Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancerJavier A Menendez, Ruth Lupu, Ramon Colomer
Breast Cancer Research and Treatment|March 5, 2004
Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere)Javier A Menendez, Ruth Lupu, Ramon Colomer
Medical Hypotheses|December 21, 2004
Inhibition of fatty acid synthase-dependent neoplastic lipogenesis as the mechanism of gamma-linolenic acid-induced toxicity to tumor cells: an extension to Nwankwo's hypothesisJavier A Menendez, Ramon Colomer, Ruth Lupu
Medical Hypotheses|December 21, 2004
Why does tumor-associated fatty acid synthase (oncogenic antigen-519) ignore dietary fatty acids?Javier A Menendez, Ramon Colomer, Ruth Lupu
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|October 16, 2010
Targeting cytoskeleton reorganisation as antimetastatic treatmentMiguel Quintela-Fandino, Antonio González-Martín, Ramon Colomer
Advances in Experimental Medicine and Biology|May 24, 2008
Her-2/neu-induced "cytokine signature" in breast cancerAlejandro Vazquez-Martin, Ramon Colomer, Javier A Menendez
Pageof 8